Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Diuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio


NEW YORK, Sept. 29, 2022 /PRNewswire/ -- The report "Diuretic Drugs Market by Product Type and Geography - Forecast and Analysis 2022-2026" has been added to Technavio's offerings. The market size is anticipated to grow by USD 95.64 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.44% during the forecast period.

Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample report is available in PDF format

Market Drivers

The increasing incidence of hypertension due to the increasing pressure on the walls of the arteries is driving the growth of the market. Hypertension raises the risk of diseases such as kidney failure, stroke, and heart disease. It can also affect the brain by causing a stroke, TIA, dementia, or mild cognitive impairment. The prevalence of hypertension in low- and middle-income countries is high. Hypertension has no warning signs or symptoms. Hence, it is also known as the silent killer. It can also cause bone loss, sexual dysfunction, and conditions such as obstructive sleep apnea (OSA). Thus, the rise in the number of patients with hypertension owing to obesity, diabetes, CKD, stress, sedentary lifestyle, and alcohol addiction will drive the growth of the market during the forecast period.

Vendor Landscape

The diuretic drugs market is concentrated, and the vendors are deploying growth strategies such as investments in R&D to compete in the market. The competition among vendors is high owing to the fast-growing sales of some of the diuretic drugs. In addition, a strong pipeline of drugs to treat high blood pressure and edema will intensify the competition further during the forecast period. The market will record the approvals for several promising drugs, which will intensify competition among vendors.

Company Profiles

The diuretic drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Casper Pharma, Hikma Pharmaceuticals Plc, Lannett Co. Inc., Novartis AG, Monarch Pharmachem, Pfizer Inc., Padagis US LLC, Sanofi, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., VITARIS AG, Validus Pharmaceuticals LLC, and Zydus Lifesciences Ltd.

Technavio's reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now

Competitive Analysis

The report includes competitive analysis, a proprietary tool to evaluate and analyze the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into categories such as growth strategies, financial performance over the last three years, new product launches, innovation score, growth in market share, investments, etc.

Market Segmentation

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

Related Reports

Motion Sickness Drugs Market by Product and Geography - Forecast and Geography 2022-2026: The motion sickness drugs market is projected to grow by USD 119.64 million from 2021 to 2026.

Antihypertensive Drugs Market by Type and Geography - Forecast and Analysis 2022-2026: The antihypertensive drugs market share is expected to increase by USD 5.87 billion from 2021 to 2026.

Diuretic Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.44%

Market growth 2022-2026

USD 95.64 million

Market structure

Concentrated

YoY growth (%)

4.29

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, Denmark, China, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Casper Pharma, Hikma Pharmaceuticals Plc, Lannett Co. Inc., Monarch Pharmachem, Novartis AG, Padagis US LLC, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, VITARIS AG, and Zydus Lifesciences Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Product Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 08:00
INT'L DAY OF PEOPLE WITH DISABILITIES: Salesian Missions highlights social and educational programs that promote inclusion Almost 1 billion people living with a disability, according to the World Health Organization. Salesian Missions, the U.S....

2 déc 2022
JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology....

2 déc 2022
AUO Display Plus (ADP) will participate in the...

2 déc 2022
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of...

2 déc 2022
New Capital Enables Growing Specialty Partnership Organization to Continue to Scale Endodontic Practice Partners (EPP), a Nashville-based specialty partnership organization, announces the securing of an additional debt facility to expand its growing...

2 déc 2022
On December 1, 2022, Mr. Wilmot Matthews acquired 5,555,556 units ("Units") of SQI Diagnostics Inc. ("SQI" or the "issuer") at a price of $0.09 per Unit or an aggregate purchase price of $500,000.04 pursuant to the closing of a non-brokered private...



News published on 29 september 2022 at 19:15 and distributed by: